{"id":"W4391689991","doi":"10.1007/s13555-023-01075-y","title":"Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; McMaster University; Dermatrials Research; Probity Medical Research; University of British Columbia; SKiN Health","funders":"Celgene; Pfizer; Eli Lilly and Company; Amgen","keywords":"Ixekizumab; Plaque psoriasis; Psoriasis; Medicine; Interleukin 17; Interleukin 23; Antagonist; Interleukin; Interleukin 1 receptor antagonist; Pharmacology; Internal medicine; Receptor antagonist; Dermatology; Secukinumab; Cytokine; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009435714,0.0004850643,0.0006386692,0.0005353168,0.0003026962,0.00008828437,0.000148016,0.0003381683,0.00003238552],"category_scores_gemma":[0.00002012968,0.0003503435,0.00005801043,0.0004130448,0.0002063527,0.0002326472,0.00006667709,0.0002763531,0.00006383161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009573392,"about_ca_system_score_gemma":0.00009565398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001607745,"about_ca_topic_score_gemma":0.0002183691,"domain_scores_codex":[0.9979208,0.0003824041,0.0003465295,0.0007591812,0.00006296165,0.0005281675],"domain_scores_gemma":[0.9990179,0.0004402377,0.00007576987,0.0002937133,0.00008235219,0.00009001425],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4134415,0.001190341,0.4939419,0.0001113371,0.006352859,0.001714646,0.01881417,0.00007306846,0.01053174,0.002829911,0.002381679,0.04861687],"study_design_scores_gemma":[0.1625859,0.02165585,0.5117925,0.002392424,0.001368657,0.004376979,0.007594587,0.0002144499,0.244273,0.0007504926,0.03805881,0.0049363],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956142,0.001842431,0.00004364333,0.0008013149,0.0004270067,0.0007928323,0.0001255866,0.0001438558,0.0002091586],"genre_scores_gemma":[0.9985375,0.0003820099,0.00008728774,0.0002287501,0.00002708919,0.00008805083,0.0001743426,0.00005381127,0.0004211872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2508556,"threshold_uncertainty_score":0.9998949,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0174092830187321,"score_gpt":0.2538951513793576,"score_spread":0.2364858683606255,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}